Clinical Trial Update: Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bortezomib with or without docetaxel in relapsed or refractory advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED